Business Context and Reporting Period
This Form 8-K filing by Neurocrine Biosciences, Inc. (NBIX) reports on the 2026 Annual Meeting of Stockholders held on May 27, 2026. The filing details the outcomes of four matters submitted to a vote by security holders, including director elections, executive compensation, equity plan amendments, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
As of the record date (March 31, 2026), 100,581,991 shares were entitled to vote, with 90,118,625 shares present. All four proposals were approved by stockholders:
- Director Elections: Three Class III nominees (Kevin C. Gorman, Gary A. Lyons, and Johanna Mercier) were elected for three-year terms expiring in 2029. Class I and Class II directors continue in office until 2027 and 2028, respectively.
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 78,993,894 votes for and 5,669,155 votes against.
- Equity Plan Amendment: Stockholders approved the amendment to the 2025 Equity Incentive Plan with 79,131,622 votes for and 5,568,926 votes against.
- Auditor Ratification: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 83,880,185 votes for and 6,170,483 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a procedural record of the Annual Meeting outcomes.
Investor Verification Checklist
- Verify the specific terms of the Amended 2025 Equity Incentive Plan in the definitive proxy statement filed on April 15, 2026.
- Confirm the composition of the Board of Directors following the election of the three new Class III members.
- Review the detailed executive compensation disclosures referenced in the proxy statement to understand the basis for the advisory vote approval.
- Note that the independent auditor for the 2026 fiscal year remains Ernst & Young LLP.